biOasis Technologies Ord Shs V.BTI.H

RE:RE:RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

[prophetoffactz]

"I can't get over the question about where xB3 went in Rathjen's activities during that time. Why has xB3 virtually disappeared?"

It hasn't dissapeared. It is being positioned stronger than ever. A much stronger more viable company in Biodexa is being created to fully exploit it internally an externally. Biodexa has lead assets in the clinic which the market demands right now as it moves away from concept stocks.Biodexa will have a stronger profile in the market. With the credibility and resources of Biodexa and validation from J&J xB3 is positioned to accelerate deal flow and its own internal xB3 pipeline. Revenue from clinical assets can support an expansive pipeline in the future limiting dilution. Data for the lead xB3 asset(Hunter) will be released in Q2 2023 around the same time Chiesi may get European and FDA approval for Fabry. A second and much stronger deal in the LSD space may be near with Chiesi capitalizing on the strength of Biodexa and advancement of xB3. Salterelli is on Chiesi's xB3 Advisory Board and he's stayed with BTI over the years and now is excited about Biodexa whose lead xB3 asset is Hunter. Again, BTI's strategic focus has been LSD's. BTI's xB3 strategic focus has been the intersection of Lysosomal Storage Disorders, inflammation, and neurodegeneration. Saltarelli has stayed. Chiesi will soon be a strategic LSD player with regulatory approval for a billion dollar indication and can't move fast enough into brain delivery given the compeition if it wants to be a strategic player in LSD. Cresence was added to xB3's strategic focus and is expandable to MS, etc., and provide clinical assets. An xB3 cancer deal can be added and Biodexa has cancer development infrastructure. Biodexa could enter a strategic alliance on xB3-Herceptin that provides financing and uses Biodexa cancer infrastructure for development. You believe there may even be a deal on Herceptin waiting. Given the cash runway to Q4 upfront money has to be coming from somewhere.